Stopped: resectable pancreatic adenocarcinoma and neuroendocrine pancreatic neoplasms are difficult to be enrolled. Pancreatic resectable cancers are treated nowadays with chemotherapy and big neuroedocrine pancreatic lesions rare
The study investigates the feasibility and the efficacy to treat pancreatic solid lesions as pancreatic adenocarcinomas (PDAC) and neuroendocrine tumors (NET) with ex-vivo radiofrequency ablation (RFA) under ultrasound (US) control. The study intent is to define the optimal radiofrequency ablation POWER of the system in terms of maximum sizes (diameters) of histological coagulative necrosis obtained at pathological samples. Results will be useful to define the optimal settings to ablate pancreatic solid lesions (PDAC and neuroendocrine tumours).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
diameter (millimeters) of coagulative necrosis obtained by RadioFrequency Ablation
Timeframe: within 15-20 days